BioSpace News Archive

Increased incidents of HAIs (hospital-acquired infections), growth in number of hospitals and surgical centres across developing economies, and strict regulations pertaining to sterilization standards in the food industry are key factors driving market growth.

Anivive, a pet health technology company transforming the therapeutic discovery and development process, announced positive results from a study on its groundbreaking fungal vaccine for Valley Fever in dogs.

Jacobio Pharmaceuticals has announced that the first two patients have been dosed in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respectively, thereby triggering the US$20 million milestone payment from AbbVie.

Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics, announced the pricing of its initial public offering of 7,000,000 American depositary shares, each representing seven ordinary shares, at a public offering price of $18.00 per ADS.

atai Life Sciences B.V., a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share.

IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the nine months ended April 30, 2021.

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.30 per share.

Rising prevalence of hepatitis diseases and growing awareness about need for early diagnosis and treatment are furling global market growth.

Rising use of illicit drugs, increasing number of drug screening labs, rising demand for presumptive tests, and increasing adoption of drug screening tests at workplace are key factors driving market growth.

IMMUNOPRECISE today announced additional results from its in vivo hamster challenge efficacy study of TATX-03a PolyTope™ Therapy.